人工髋关节感染二期再植的长期再感染与病原体结局系统综述
该系统综述纳入28项研究共2047例患者2055髋,评估慢性假体周围髋关节感染二期再植术后长期再感染风险及病原体情况。结论指出多数文献随访仅两年,但长期再感染风险显著,需更长期随访研究。
要点
- 最低随访≥24个月的研究中,24个月再感染率为4.58%,最终随访升至7.34%。
- 新病原体再感染率为3.00%,复发病原体再感染率为1.70%。
核心结论
- 二期再植术后长期再感染风险显著,多数文献随访仅两年,需更长期随访研究以识别晚期感染相关因素。
研究设计与样本
- 系统综述纳入随机对照试验、队列研究和病例系列,初检320篇摘要,全文审阅138篇,最终纳入28项研究共2047例患者2055髋,均完成二期再植,仅7项研究随访超过24个月。
临床怎么用
- 临床应认识到二期再植术后长期再感染风险,尤其在随访超过5年时再感染率可达10.25%,需延长随访监测。
- 再感染既可由新病原体也可由复发病原体引起,病原学诊断对指导治疗有重要意义。
局限性
- 仅7项研究随访超过24个月,长期数据有限。
- 仅12项研究报告原发与再感染病原体数据,病原体分析受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although two-stage exchange for chronic periprosthetic hip infections remains an effective option for infection eradication, long-term outcome reporting remains scarce. Compiling outcomes data for this standard of care is necessary to characterize long-term reinfection risk and identify bacteria associated with reinfection. The purpose of our study was to perform a systematic review to determine the long-term risk of reinfection after two-stage reimplantation. The second purpose was to identify the proportion of reinfections caused by the same or different organism(s) relative to the index infection. METHODS: We performed a systematic review of two-stage reimplantation randomized control trials, cohort studies, and case series for the treatment of periprosthetic joint infections, yielding 320 unique citations for abstract review, of which 138 were reviewed in full. We collected reinfection data including the timing of reinfection after successful reimplantation and the bacteria identified at reinfection. Meeting inclusion criteria were 28 studies with 2047 patients and 2055 hips that completed both reimplantation stages with just seven studies having greater than 24 month follow-up. RESULTS: Studies with longer average follow-up reported significantly higher all-time reinfection rates (P = .042). Among studies with at least 5 years of follow-up, the risk of reinfection was 10.25% (8.21-12.47). Among studies with minimum follow-up of at least 24 months, the 24-month rate of reinfection was 4.58% (2.17-7.66), which increased to 7.34% (4.44-10.82) by final follow-up. Only 12 studies reported index and recurrent pathogen data. In those studies, 3.00% (1.19-5.38) of all hips which completed both reimplantation stages were reinfected by a new pathogen, and 1.70% (0.52-3.35) of patients became reinfected by recurrent pathogens. CONCLUSION: While the majority of two stage reimplantation literature follows patients for two years, there is significant risk of reinfection into the long term. Further studies with detailed outcomes and long-term follow-up are needed to identify factors associated with late infections.
引用
- Otten MR, Kildow BJ, Sayles HR, et al. Two-Stage Reimplantation of a Prosthetic Hip Infection: Systematic Review of Long-Term Reinfection and Pathogen Outcomes. J Arthroplasty. 2021. PMID: 33736896. doi:10.1016/j.arth.2021.02.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。